Breaking Ground: From CPAP Treatment to the First Medicine for OSA Patients with Obesity

被引:1
|
作者
Lisik, Daniil [1 ,2 ]
Zou, Ding [2 ]
机构
[1] Univ Gothenburg, Inst Med, Sahlgrenska Acad, Krefting Res Ctr, S-40530 Gothenburg, Sweden
[2] Univ Gothenburg, Sahlgrenska Acad, Inst Med, Ctr Sleep & Vigilance Disorders, Medicinaregatan 8B,Box 421, S-40530 Gothenburg, Sweden
关键词
Drug treatment; GLP-1 receptor agonist; Obstructive sleep apnea; Phenotype; Precision medicine; Treatable trait; OBSTRUCTIVE SLEEP-APNEA; POSITIVE AIRWAY PRESSURE; EXCESSIVE DAYTIME SLEEPINESS; ORAL APPLIANCE; HEALTH OUTCOMES; WEIGHT-LOSS; LOOP GAIN; THERAPY; ACETAZOLAMIDE; ADHERENCE;
D O I
10.1007/s13665-024-00365-w
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Purpose of Review Pharmacologic alternatives in management of obstructive sleep apnea (OSA) have been pursued for decades. Considering rapid development and promising findings in recent years, we provide an overview of novel agents and treatment targets, ongoing trials, as well as future perspectives.Recent Findings Several drugs demonstrate efficacy, though none is sufficient to cure the disease as a monotherapy. Instead, the main potential lies in applying drug therapy in specific subgroups or as an addition to established treatments (e.g., positive airway pressure, oral appliance therapy). Glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists may be particularly beneficial in obese OSA patients. As a major breakthrough, terzipatide, a GIP analog and GLP-1 receptor agonist, has become the first FDA-approved and EMA-sanctioned pharmacologic treatment option of OSA in obese individuals. Beyond this, alerting drugs could help manage residual daytime sleepiness and improve daytime functioning. However, long-term studies on safety, adherence, and effectiveness are scarce and highlight certain limitations and challenges.Summary Incorporating pharmaceuticals along conventional OSA management may provide synergy benefit in certain patients, but side-effects and risk reduction of related adverse outcomes over time is yet to be assessed. Furthermore, guidelines/frameworks for mapping out applicable treatment targets are needed.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Acylated ghrelin level in patients with OSA before and after nasal CPAP treatment
    Takahashi, Ken-ichi
    Chin, Kazuo
    Akamizu, Takashi
    Morita, Satoshi
    Sumi, Kensuke
    Oga, Toru
    Matsumoto, Hisako
    Niimi, Akio
    Tsuboi, Tomomasa
    Fukuhara, Shunichi
    Kangawa, Kenji
    Mishima, Michiaki
    RESPIROLOGY, 2008, 13 (06) : 810 - 816
  • [22] SLEEP STUDIES IN OSA PATIENTS BEFORE CPAP TREATMENT - ONE NIGHT OR 2
    ORR, WC
    CHEST, 1993, 103 (02) : 652 - 653
  • [23] The effect of CPAP and oral appliances treatment on biomarkers in patients with heart failure and OSA
    Andreieva, I.
    EUROPEAN JOURNAL OF HEART FAILURE, 2019, 21 : 222 - 222
  • [24] Ground-breaking treatment for dialysis patients
    不详
    EXPERT REVIEW OF MEDICAL DEVICES, 2004, 1 (01) : 3 - 3
  • [25] Impacts of long-term CPAP therapy on fatty liver in male OSA patients with abdominal obesity
    Toyama, Yoshiro
    Murase, Kimihiko
    Azuma, Masanori
    Hamada, Satoshi
    Tachikawa, Ryo
    Kubo, Takeshi
    Tanizawa, Kiminobu
    Inouch, Morito
    Handa, Tomohiro
    Hitomi, Takefumi
    Oga, Toru
    Mishima, Michiaki
    Chin, Kazuo
    EUROPEAN RESPIRATORY JOURNAL, 2014, 44
  • [26] PROGRESS IN THE SUPRA TRIAL FOR THE TREATMENT OF CPAP-INTOLERANT OSA PATIENTS: AHI AND SAFETY
    Strohl, Kingman
    Mehra, Reena
    Patel, Sanjay
    Pena-Orbea, Ciythya
    Bogan, Richard
    Magalang, Ulysses
    SLEEP, 2023, 46
  • [27] THE EFFECT OF APAP AND CPAP TREATMENT ON THE NOCTURNAL BLOOD PRESSURE FLUCTUATION IN OSA WITH HYPERTENSION PATIENTS
    Jiang, X.
    Zhang, Q.
    Shi, J.
    Chen, D.
    Han, M.
    Li, M.
    Da, P.
    Ma, S.
    He, Z.
    Han, F.
    SLEEP MEDICINE, 2022, 100 : S282 - S282
  • [28] OBSTRUCTIVE SLEEP APNOEA (OSA) AND RESPONSE TO CPAP TREATMENT IN PATIENTS WITH CHRONIC OPIOID USE
    Lee, K.
    Mason, M.
    Smith, I.
    THORAX, 2018, 73 : A128 - A129
  • [29] Driving Simulator Performance Remains Impaired In Patients With Severe OSA after CPAP Treatment
    Vakulin, Andrew
    Baulk, Stuart D.
    Catcheside, Peter G.
    Antic, Nick A.
    van den Heuvel, Cameron J.
    Dorrian, Jillian
    McEvoy, R. Doug
    JOURNAL OF CLINICAL SLEEP MEDICINE, 2011, 7 (03): : 243 - 250
  • [30] Why excessive sleepiness may persist in OSA patients receiving adequate CPAP treatment
    Castiglioni, P.
    Lombardi, C.
    Cortelli, P.
    Parati, G.
    EUROPEAN RESPIRATORY JOURNAL, 2012, 39 (01) : 226 - 227